



CURRICULUM VITAE

SIGNATURE:		DATE:	14 Jul 14
NAME:	Suhail H. Zavaro, MD	DATE UPDATED:	July 2014
TITLE:	Principal Investigator		

RESEARCH SITE ADDRESS & PHONE:

Main Office: TriWest Research Associates, LLC 300 South Pierce Street. Suite 201 El Cajon, CA 92020	Contact Info: Office: (619) 334-4735 Fax: (619) 334-4769 Email: drzavaro@trivestresearch.com
---	--

EDUCATION/TRAINING:

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Brown University Integrated Hospital The Miriam Hospital Providence, Rhode Island		1987-1988	Interventional Cardiology
Brown University Integrated Hospital Providence, Rhode Island		1985-1987	Cardiology Fellowship Program
Brown University Medicine The Miriam Hospital Providence, Rhode Island		1983-1985	Internal Medicine Residency
Trenton Affiliated Hospitals Trenton, New Jersey		1983-1985	Internship
Aleppo University School of Medicine Aleppo, Syria	M.D	1969-1975	Medicine

BOARD CERTIFIED:

BOARD CERTIFIED/ELIGIBLE	YEAR(s)	SPECIALTY
Board Certified Medical License	1999	Interventional Cardiology

Board Certified Medical License	1991	Critical Care Medicine
Board Certified Medical License	1987	Cardiovascular Disease
Board Certified Medical License	1985	Internal Medicine

POSITIONS AND EMPLOYMENT:

2012-Present	Principal Investigator, TriWest Research Associates LLC, El Cajon, CA
2000-Present	Physician, Zavaro Cardiovascular Institute, El Cajon, CA
2003-Present	Medical Director of Cardiology, Grossmont Hospital, La Mesa, CA
1999-2000	Medical Director Grossmont Heart Center, La Mesa, CA
1995	Clinical Assistant professor of Medicine, University of Wisconsin, Madison, WI
1988-1999	Interventional Cardiologist, Marshfield Clinic, Saint Joseph Hospital, Marshfield, WI
1988-1990	Director of CME, Department of Cardiology, Marshfield Clinic, Marshfield, WI
1976-1982	General Medical Practice, Kamishly, Syria

PUBLICATIONS:

Thesis on the Treatment of Essential Hypertension

Letter to Editor, "Psychotropic Drug Use in the Elderly", New England Journal of Medicine, March edition, p. 652

Zavaro and Grierson, "Mitral Balloon Valvuloplasty", Marshfield Clinic Bulletin 1992; 28: 19-29

OTHERS:

February 25, 2012 Conference Chair, Cardiology Conference for Primary Care Physician, Sharp Healthcare, San Diego, CA

CLINICAL RESEARCH EXPERIENCE:

The Safety of Biplane Coronary Angiographies in Patients with renal failure

Yale University School of Medicine, The Virgo Trial, Variation In Recovery; Role of Gender on Outcomes of Young AMI patients.

The Champion Phoenix Trial; Cangrelor versus standard therapy to Achieve Optimal Management of Platelet Inhibition.

Bayer: A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral XXXX compared to vitamin K antagonist (VKA) for the prevention of cardiovascular events in subjects with nonvalvular atrial fibrillation scheduled for cardioversion

Takeda: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of XXXX, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events

AstraZeneca Pharmaceuticals LP: A randomized, double-blind, parallel group, multicenter phase IIIb study to compare XXXX with XXXX treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease (EUCLID-Examining Use of ticagrelor in PAD)

Regeneron: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of 3-Month Subcutaneous XXXX Treatment in Patients with Sarcopenia

Pfizer Inc: Phase 3 Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group evaluation of the efficacy, safety, and tolerability of XXXX, in reducing the occurrence of major cardiovascular events in high risk subjects

Pfizer Inc: Phase 3 Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group evaluation of the efficacy, safety, and tolerability of XXXX, in reducing the occurrence of major cardiovascular events in high risk subjects

Novartis: A 56-week, randomized, multi-center, double-blind, placebo-controlled, phase IIa/IIb study to evaluate the safety and efficacy of i.v. bimagrumab on total lean body mass and physical performance in patients after surgical treatment of hip fracture